Literature DB >> 12090274

HIV-1 diversity and vaccine development.

Gary Nabel, William Makgoba, Jose Esparza.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12090274     DOI： 10.1126/science.296.5577.2335

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  10 in total

1.  Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge.

Authors:  Yue Sun; Jörn E Schmitz; Adam P Buzby; Brianne R Barker; Srinivas S Rao; Ling Xu; Zhi-Yong Yang; John R Mascola; Gary J Nabel; Norman L Letvin
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 env evolves toward ancestral states upon transmission to a new host.

Authors:  Joshua T Herbeck; David C Nickle; Gerald H Learn; Geoffrey S Gottlieb; Marcel E Curlin; Laura Heath; James I Mullins
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

Review 3.  Polyvalent AIDS vaccines.

Authors:  Shan Lu; Jill M Grimes Serrano; Shixia Wang
Journal:  Curr HIV Res       Date:  2010-12       Impact factor: 1.581

4.  Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity.

Authors:  Yasushi Ami; Yasuyuki Izumi; Kazuhiro Matsuo; Kenji Someya; Masaru Kanekiyo; Shigeo Horibata; Naoto Yoshino; Koji Sakai; Katsuaki Shinohara; Sohkichi Matsumoto; Takeshi Yamada; Shudo Yamazaki; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

5.  Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.

Authors:  Kenji Someya; Dayaraj Cecilia; Yasushi Ami; Tadashi Nakasone; Kazuhiro Matsuo; Sherri Burda; Hiroshi Yamamoto; Naoto Yoshino; Masahiko Kaizu; Shuji Ando; Kenji Okuda; Susan Zolla-Pazner; Shudo Yamazaki; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

6.  Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.

Authors:  Barney S Graham; Richard A Koup; Mario Roederer; Robert T Bailer; Mary E Enama; Zoe Moodie; Julie E Martin; Margaret M McCluskey; Bimal K Chakrabarti; Laurie Lamoreaux; Charla A Andrews; Phillip L Gomez; John R Mascola; Gary J Nabel
Journal:  J Infect Dis       Date:  2006-11-08       Impact factor: 5.226

7.  Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.

Authors:  Andrew T Catanzaro; Richard A Koup; Mario Roederer; Robert T Bailer; Mary E Enama; Zoe Moodie; Lin Gu; Julie E Martin; Laura Novik; Bimal K Chakrabarti; Bryan T Butman; Jason G D Gall; C Richter King; Charla A Andrews; Rebecca Sheets; Phillip L Gomez; John R Mascola; Gary J Nabel; Barney S Graham
Journal:  J Infect Dis       Date:  2006-11-08       Impact factor: 5.226

8.  Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys.

Authors:  Michael S Seaman; Ling Xu; Kristin Beaudry; Kristi L Martin; Margaret H Beddall; Ayako Miura; Anna Sambor; Bimal K Chakrabarti; Yue Huang; Robert Bailer; Richard A Koup; John R Mascola; Gary J Nabel; Norman L Letvin
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope.

Authors:  N A Doria-Rose; G H Learn; A G Rodrigo; D C Nickle; F Li; M Mahalanabis; M T Hensel; S McLaughlin; P F Edmonson; D Montefiori; S W Barnett; N L Haigwood; J I Mullins
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

10.  Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization.

Authors:  Igor M Belyakov; Jeffrey D Ahlers; Gary J Nabel; Bernard Moss; Jay A Berzofsky
Journal:  Virology       Date:  2008-09-14       Impact factor: 3.616
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.